TABLE 2.
Prevalence of genomic alterations in the NSCLC PD-L1TPS≥50 and NSCLC PD-L1TPS<50 cohorts and comparison of the two groups using Fisher Exact Test with Bonferroni adjusted p-value.
| PD-L1 ≥ 50 (n = 2,885) | n | PD-L1 < 50 (n = 6,565) | n | Adjusted p-value | |
|---|---|---|---|---|---|
| EGFR mutations | 10.1% | 292 | 15.7% | 1,030 | <0.001 |
| BRAF mutations | 5.6% | 163 | 3.6% | 237 | <0.001 |
| ALK rearrangements | 3.0% | 86 | 2.2% | 142 | 0.236 |
| ROS1 rearrangements | 0.9% | 26 | 0.6% | 37 | 0.886 |
| NTRK fusions | 0.1% | 4 | 0.2% | 11 | 1 |
| RET rearrangements | 0.8% | 22 | 0.6% | 41 | 1 |
| ERBB2 mutations | 1.1% | 32 | 2.0% | 130 | 0.030 |
| MET mutations | 4.6% | 133 | 1.4% | 92 | <0.001 |
| MET amplifications | 5.3% | 153 | 1.6% | 103 | <0.001 |
| KRAS mutations | 36.7% | 1,058 | 25.4% | 1,670 | <0.001 |
| STK11 mutations | 6.2% | 179 | 15.0% | 982 | <0.001 |
| KEAP1 mutations | 4.9% | 142 | 6.4% | 417 | <0.001 |